Bank of New York Mellon’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-307,764
| Closed | -$936K | – | 4196 |
|
|
2024
Q4 | $936K | Sell |
307,764
-18,519
| -6% | -$80.7K | ﹤0.01% | 3206 |
|
|
2024
Q3 | $1.69M | Sell |
326,283
-46,732
| -13% | -$232K | ﹤0.01% | 2837 |
|
|
2024
Q2 | $959K | Buy |
373,015
+68,451
| +22% | +$234K | ﹤0.01% | 3228 |
|
|
2024
Q1 | $1.5M | Sell |
304,564
-30,621
| -9% | -$181K | ﹤0.01% | 2924 |
|
|
2023
Q4 | $2.95M | Sell |
335,185
-50,476
| -13% | -$414K | ﹤0.01% | 2635 |
|
|
2023
Q3 | $4.42M | Buy |
385,661
+13,152
| +4% | +$253K | ﹤0.01% | 2384 |
|
|
2023
Q2 | $9.43M | Buy |
372,509
+63,130
| +20% | +$1.97M | ﹤0.01% | 1975 |
|
|
2023
Q1 | $9.97M | Sell |
309,379
-3,316
| -1% | -$103K | ﹤0.01% | 1934 |
|
|
2022
Q4 | $5.77M | Buy |
312,695
+3,533
| +1% | +$80.8K | ﹤0.01% | 2262 |
|
|
2022
Q3 | $8.35M | Buy |
309,162
+50,198
| +19% | +$1.02M | ﹤0.01% | 2002 |
|
|
2022
Q2 | $3.58M | Sell |
258,964
-15,575
| -6% | -$240K | ﹤0.01% | 2497 |
|
|
2022
Q1 | $5.35M | Sell |
274,539
-1,705
| -0.6% | -$25.9K | ﹤0.01% | 2386 |
|
|
2021
Q4 | $4.51M | Buy |
276,244
+5,691
| +2% | +$94.9K | ﹤0.01% | 2520 |
|
|
2021
Q3 | $7.54M | Buy |
270,553
+19,775
| +8% | +$564K | ﹤0.01% | 2277 |
|
|
2021
Q2 | $7.43M | Sell |
250,778
-125,820
| -33% | -$3.63M | ﹤0.01% | 2288 |
|
|
2021
Q1 | $10.5M | Buy |
376,598
+18,676
| +5% | +$517K | ﹤0.01% | 2057 |
|
|
2020
Q4 | $10.1M | Buy |
357,922
+44,618
| +14% | +$1.16M | ﹤0.01% | 2000 |
|
|
2020
Q3 | $7.88M | Buy |
313,304
+33,933
| +12% | +$890K | ﹤0.01% | 1978 |
|
|
2020
Q2 | $6.82M | Buy |
279,371
+17,513
| +7% | +$346K | ﹤0.01% | 2053 |
|
|
2020
Q1 | $3.88M | Sell |
261,858
-66,006
| -20% | -$1.37M | ﹤0.01% | 2206 |
|
|
2019
Q4 | $5.32M | Sell |
327,864
-746,842
| -69% | -$11.6M | ﹤0.01% | 2309 |
|
|
2019
Q3 | $14M | Sell |
1,074,706
-1,179,091
| -52% | -$14.4M | ﹤0.01% | 1740 |
|
|
2019
Q2 | $29.2M | Sell |
2,253,797
-38,988
| -2% | -$491K | 0.01% | 1312 |
|
|
2019
Q1 | $36.1M | Sell |
2,292,785
-249,457
| -10% | -$4.33M | 0.01% | 1180 |
|
|
2018
Q4 | $51.2M | Buy |
2,542,242
+77,625
| +3% | +$1.71M | 0.02% | 865 |
|
|
2018
Q3 | $61.2M | Buy |
2,464,617
+519,938
| +27% | +$14.1M | 0.02% | 883 |
|
|
2018
Q2 | $53.4M | Sell |
1,944,679
-68,553
| -3% | -$2.06M | 0.01% | 956 |
|
|
2018
Q1 | $62M | Sell |
2,013,232
-131,437
| -6% | -$4.23M | 0.02% | 862 |
|
|
2017
Q4 | $76.7M | Buy |
2,144,669
+135,356
| +7% | +$3.89M | 0.02% | 763 |
|
|
2017
Q3 | $55.4M | Sell |
2,009,313
-70,249
| -3% | -$1.7M | 0.02% | 917 |
|
|
2017
Q2 | $54.9M | Buy |
2,079,562
+261,764
| +14% | +$5.84M | 0.02% | 904 |
|
|
2017
Q1 | $37.8M | Sell |
1,817,798
-123,932
| -6% | -$2.55M | 0.01% | 1137 |
|
|
2016
Q4 | $40.2M | Buy |
1,941,730
+18,622
| +1% | +$312K | 0.01% | 1070 |
|
|
2016
Q3 | $31.2M | Sell |
1,923,108
-195,450
| -9% | -$2.84M | 0.01% | 1170 |
|
|
2016
Q2 | $28.8M | Buy |
2,118,558
+152,383
| +8% | +$2.69M | 0.01% | 1170 |
|
|
2016
Q1 | $34.3M | Sell |
1,966,175
-43,392
| -2% | -$883K | 0.01% | 1067 |
|
|
2015
Q4 | $68.6M | Buy |
2,009,567
+98,080
| +5% | +$3.4M | 0.02% | 709 |
|
|
2015
Q3 | $56.9M | Buy |
1,911,487
+71,346
| +4% | +$2.17M | 0.02% | 780 |
|
|
2015
Q2 | $58.8M | Buy |
1,840,141
+675,847
| +58% | +$17.4M | 0.02% | 817 |
|
|
2015
Q1 | $24.1M | Buy |
1,164,294
+140,872
| +14% | +$2.43M | 0.01% | 1356 |
|
|
2014
Q4 | $17.3M | Buy |
1,023,422
+939,438
| +1,119% | +$16.4M | ﹤0.01% | 1572 |
|
|
2014
Q3 | $1.62M | Sell |
83,984
-25,443
| -23% | -$663K | ﹤0.01% | 3019 |
|
|
2014
Q2 | $3.72M | Buy |
109,427
+91,133
| +498% | +$2.86M | ﹤0.01% | 2505 |
|
|
2014
Q1 | $576K | Buy |
+18,294
| New | +$572K | ﹤0.01% | 3535 |
|
Other funds holding RVNC
Bank of New York Mellon's RVNC Position: Q1 2025 in Review
Bank of New York Mellon sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 307,764 shares — an estimated $936K sold.
Bank of New York Mellon first reported a position in RVNC in Q1 2014 and held it in 44 quarters. The position peaked at $76.7M in Q4 2017. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Bank of New York Mellon reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Bank of New York Mellon sold 307,764 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $936K.
- Bank of New York Mellon first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 44 quarters.
- Bank of New York Mellon's Revance Therapeutics, Inc. position peaked at $76.7M in Q4 2017.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Bank of New York Mellon's 13F filing for Q1 2025, filed 29 Apr 2025.